Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05587504 · ClinicalTrials.gov registry record · NA
Determination of Liquid Flavor and Nicotine Form Outcomes
A NA study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT05587504: Completed NA study, sponsored by Virginia Commonwealth University.
NCT05587504 is a NA study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05587504, a NA study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out how different types of electronic cigarette/vape e-liquids with differing sweetness and forms of nicotine affect blood nicotine levels, use behavior (how people puff), and how people feel.
Primary Outcome
Blood will be taken multiple times in each session to examine changes in plasma nicotine concentration from baseline to after various e-cigarette or cigarette usage.
Interventions
- OTHER E-cigarette with sweetness type 1 and pronation level 1
- OTHER E-cigarette with sweetness type 1 and pronation level 2
- OTHER E-cigarette with sweetness type 2 and pronation level 1
- OTHER E-cigarette with sweetness type 2 and pronation level 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2023-07-21 |
| Est. Completion | 2024-07-24 |
| Phase | NA |
What the finished NCT05587504 record still lists
NCT05587504 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 4 interventions - of which E-cigarette with sweetness type 1 and pronation level 1 is the first listed.
NCT05587504 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05587504 about?
NCT05587504 is a clinical study titled "Determination of Liquid Flavor and Nicotine Form Outcomes". The purpose of this research study is to find out how different types of electronic cigarette/vape e-liquids with differing sweetness and forms of nicotine affect blood nicotine levels, use behavior (how people puff), and how people feel.
What is the current status of trial NCT05587504?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2023-07-21. Estimated completion is 2024-07-24.
What interventions are being tested in trial NCT05587504?
The interventions under investigation include: E-cigarette with sweetness type 1 and pronation level 1 (OTHER), E-cigarette with sweetness type 1 and pronation level 2 (OTHER), E-cigarette with sweetness type 2 and pronation level 1 (OTHER), E-cigarette with sweetness type 2 and pronation level 2 (OTHER).
Who is sponsoring clinical trial NCT05587504?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05587504's enrollment target sits among peer trials
13 1911th of 2000 higher than 88 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI